News & Updates
Filter by Specialty:
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
27 Oct 2022
Ridinilazole triggers clinical response in CDI, inhibits recurrence
In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).
Ridinilazole triggers clinical response in CDI, inhibits recurrence
27 Oct 2022
Vitamin D, aspirin, exercise reduce pregnancy-related hypertension
There appears to be several ways to reduce the risk of pre-eclampsia and pregnancy-induced hypertension. These include low molecular weight heparin (LMWH), vitamin D supplementation, calcium supplementation, aspirin, and exercise, according to a meta-analysis.
Vitamin D, aspirin, exercise reduce pregnancy-related hypertension
27 Oct 2022
Statins show therapeutic potential in COVID-19-related acute kidney injury
COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.
Statins show therapeutic potential in COVID-19-related acute kidney injury
26 Oct 2022
Tenofovir alafenamide reduces liver stiffness in CHB patients
Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.
Tenofovir alafenamide reduces liver stiffness in CHB patients
26 Oct 2022
Cefepime-taniborbactam trumps meropenem for complicated UTI
Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.
Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).